BACTIGUARD HOLDING AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 68.8 SEK | +2.08% |
|
+1.47% | +11.33% |
| May. 14 | Bactiguard Holding Ab Appoints Thomas Von Koch as the Chairman of the Board of Directors | CI |
| Apr. 25 | Transcript : Bactiguard Holding AB, Q1 2024 Earnings Call, Apr 25, 2024 |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Weaknesses
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +11.33% | 229M | C- | ||
| +12.88% | 28.64B | B+ | ||
| +23.84% | 2.59B | - | A- | |
| +25.93% | 2.49B | B | ||
| -46.39% | 2.39B | B- | ||
| -30.42% | 2.09B | C+ | ||
| +32.22% | 2.04B | B | ||
| -22.93% | 1.63B | - | ||
| +14.34% | 1.45B | - | ||
| +31.89% | 1.33B | C |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- BACTI B Stock
- Ratings Bactiguard Holding AB
